Publicații

PUBLICAȚII

Xander, N.S.H., Belleman, T., Salcher-Konrad, M. et al. Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review. Eur J Health Econ (2025). https://doi.org/10.1007/s10198-025-01834-y
Henkel, P. S., Aas, E., Russnes, H. G., Dyvik, I., Fagereng, G. L., Helland, Å., Røgenes, H., Lien, T. G., & Pedersen, K. (2025). Microcosting Study of Genomic Profiling for Precision Cancer Medicine: Application from the National Infrastructure for Precision Diagnostics in Norway. The Journal of Molecular Diagnostics. Advance online publication, July 22, 2025. https://doi.org/10.1016/j.jmoldx.2025.06.006
Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils, Carin A. Uyl-de Groot, Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands, Value in Health, 2024,
https://doi.org/10.1016/j.jval.2024.06.003
Heine RJSD, Thielen FW, Mathijssen RHJ, van Leeuwen RWF, Franken MG, et al. (2024) Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab. PLOS ONE 19(2): e0293264. https://doi.org/10.1371/journal.pone.0293264

B.P. Geisler, S. Meltzer, E.A. Burger, E. Aas, A.H.Ree: Value of immune checkpoint blockade (ICB) in microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). Annals of Oncology 35:S936-S937 DOI: 10.1016/j.annonc.2024.08.1599 https://www.annalsofoncology.org/article/S0923-7534(24)03118-1/pdf
B.P. Geisler, S. Meltzer, E.A. Burger, A.H. Ree, E. Aas: Cost-effectiveness of Next Generation Sequencing to Select Microsatellite Stable/Mismatch Repair Proficient Metastatic Colorectal Cancer Patients for Immune Checkpoint Inhibitor Therapy. Abstract forthcoming in a Value in Health Supplement. Rezumat în curs de publicare într-un supliment Value in Health.
Salcher-Konrad M, Hendrickx A, Schneider P, Zimmermann N. Defining fair prices for new health technologies. 5th PPRI conference 2024: Ensuring access to affordable medicines through innovative policies, Vienna, 25–26 April 2024
Salcher-Konrad M, Zimmermann N, Schneider P, Hendrickx A: What is a fair price? A review of definitions for fair prices of health technologies . ISPOR Europe 2023, Copenhagen, 14 November 2023